Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
15.80
Nov 13 • 3:59 PM ET Dollar change+1.44 Percentage change(10.03%)
Aftermarket Close
15.49
Aftermarket • 7:30 PM ET Dollar change-0.31 Percentage change(-1.96%)
Index
-
Market Cap
4.31B
Enterprise Value
4.72B
Income
163.03M
Sales
1.45B
Book/sh
6.63
Cash/sh
0.48
Employees
-
IPO
Jul 16, 2021
P/E
26.46
Forward P/E
21.74
PEG
1.72
P/S
2.98
P/B
2.38
P/C
33.05
P/FCF
299.13
EV/EBITDA
12.80
EV/Sales
3.25
Quick Ratio
1.19
Current Ratio
1.73
Debt/Eq
0.29
LT Debt/Eq
0.22
Option/Short
Yes / Yes
EPS (ttm)
0.60
EPS next Y
0.73
EPS next Q
0.22
EPS this Y
14.18%
EPS next Y
6.91%
EPS next 5Y
12.66%
EPS past 3/5Y
0.64% 11.33%
Sales past 3/5Y
9.00% 12.15%
EPS Y/Y TTM
4.96%
Sales Y/Y TTM
11.99%
EPS Q/Q
14.12%
Sales Q/Q
5.89%
Insider Own
82.08%
Insider Trans
0.01%
Inst Own
17.03%
Inst Trans
-0.91%
ROA
5.56%
ROE
9.32%
ROIC
7.41%
Gross Margin
28.84%
Oper. Margin
17.58%
Profit Margin
11.25%
SMA20
-7.00%
SMA50
-17.50%
SMA200
-11.82%
Trades
Shs Outstand
49.83M
Shs Float
48.94M
52W High
24.01 -34.19%
52W Low
12.05 31.12%
Volatility
6.46% 6.26%
ATR (14)
1.14
RSI (14)
42.54
Beta
0.81
Rel Volume
2.37
Avg Volume
615.17K
Volume
1,458,093
Perf Week
16.43%
Perf Month
-17.92%
Perf Quarter
-25.68%
Perf Half Y
-12.17%
Perf YTD
-21.47%
Perf Year
-30.27%
Perf 3Y
-45.21%
Perf 5Y
-28.83%
Perf 10Y
-
Prev Close
14.36
Price
15.80
Change %
10.03%
Consensus
Buy
Avg. Price Target
$19.57
Implied Upside
+23.9%
Analysts14incl. previous ratings
Rating Distribution9 Buy · 5 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 04, 2026Downgrade
WWilliam Blair
Outperform → Mkt Perform
Oct 07, 2026Initiated
DB logoDDeutsche Bank
Hold
Sep 09, 2026Initiated
UBS logoUUBS
Neutral
Jun 16, 2026Initiated
TD logoTTD Cowen
Buy$25+58.2%
Jun 02, 2026Resumed
WWolfe Research
Outperform$21+32.9%
Dec 02, 2025Resumed
MS logoMMorgan Stanley
Equal-Weight$24+51.9%
Dec 13, 2024Initiated
WWolfe Research
Outperform$28+77.2%
Dec 03, 2024Resumed
MS logoMMorgan Stanley
Equal-Weight$23+45.6%
Apr 22, 2024Initiated
EExane BNP Paribas
Outperform
Nov 01, 2023Downgrade
JEF logoJJefferies
Buy → Hold$39 → $29+83.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FEDERICI WILLIAM JDirectorNov 09 '26Buy13.7220,000274,40046,991Nov 12 04:30 PM
MOREL DONALD E JRDirectorNov 06 '26Buy13.0725,000326,75062,424Nov 10 04:30 PM
Stocchi MauroSee RemarksSep 28 '26Sale21.5013,649293,454400,000Sep 30 05:20 PM
Mauro StocchiOfficerSep 14 '26Proposed Sale20.2413,649276,255Sep 14 09:57 AM
Santel LucianoDirectorAug 07 '26Sale20.092,02340,6424,739Aug 10 04:15 PM
Dal Lago MarcoChief Financial OfficerAug 07 '26Sale20.094,20984,55981,144Aug 10 04:15 PM
Magistretti ElisabettaDirectorAug 07 '26Sale20.092,04541,0842,930Aug 10 04:15 PM
Dal Lago MarcoChief Financial OfficerAug 07 '26Proposed Sale20.094,20984,555Aug 07 11:56 AM
Balachandran MadhavanDirectorJun 15 '26Sale17.091,49325,51569,458Jun 26 06:18 AM
Dal Lago MarcoChief Financial OfficerJun 12 '26Option Exercise0.007,997085,353Jun 26 06:16 AM
MOREL DONALD E JRDirectorJun 15 '26Sale17.091,49325,51537,424Jun 26 06:12 AM
Stocchi MauroSee RemarksJun 09 '26Option Exercise0.006,5860413,629Jun 26 06:07 AM
Flynn KarenDirectorJun 15 '26Sale17.091,49325,5155,757Jun 26 06:05 AM
FEDERICI WILLIAM JDirectorJun 15 '26Sale17.091,49325,51526,991Jun 26 06:04 AM
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.
CEO & Executive ChairmanMr. Franco Stevanato
Chief Financial OfficerMr. Marco Dal Lago
Chief Communications & Investor Relations OfficerMs. Lisa Miles
Chief Human Resources OfficerMs. Carla Costa
Chief Business Strategy OfficerMr. Mauro Stocchi